CL2018003681A1 - Derivados de ácido borónico y usos terapéuticos de los mismos - Google Patents
Derivados de ácido borónico y usos terapéuticos de los mismosInfo
- Publication number
- CL2018003681A1 CL2018003681A1 CL2018003681A CL2018003681A CL2018003681A1 CL 2018003681 A1 CL2018003681 A1 CL 2018003681A1 CL 2018003681 A CL2018003681 A CL 2018003681A CL 2018003681 A CL2018003681 A CL 2018003681A CL 2018003681 A1 CL2018003681 A1 CL 2018003681A1
- Authority
- CL
- Chile
- Prior art keywords
- acid derivatives
- boronic acid
- therapeutic uses
- compositions
- lactamasa
- Prior art date
Links
- 150000001642 boronic acid derivatives Chemical class 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- -1 FOR EXAMPLE Substances 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357165P | 2016-06-30 | 2016-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003681A1 true CL2018003681A1 (es) | 2019-04-26 |
Family
ID=60785544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003681A CL2018003681A1 (es) | 2016-06-30 | 2018-12-19 | Derivados de ácido borónico y usos terapéuticos de los mismos |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10294249B2 (enExample) |
| EP (1) | EP3478693B1 (enExample) |
| JP (1) | JP7060245B2 (enExample) |
| KR (1) | KR102403296B1 (enExample) |
| CN (1) | CN109415386B (enExample) |
| AU (1) | AU2017290060B2 (enExample) |
| BR (1) | BR112018077015B1 (enExample) |
| CA (1) | CA3026582A1 (enExample) |
| CL (1) | CL2018003681A1 (enExample) |
| CO (1) | CO2018013978A2 (enExample) |
| DK (1) | DK3478693T3 (enExample) |
| ES (1) | ES2894251T3 (enExample) |
| IL (1) | IL263450B (enExample) |
| MX (1) | MX389349B (enExample) |
| MY (1) | MY196909A (enExample) |
| PH (1) | PH12018502747A1 (enExample) |
| PL (1) | PL3478693T3 (enExample) |
| PT (1) | PT3478693T (enExample) |
| SA (1) | SA518400742B1 (enExample) |
| SG (1) | SG11201811549UA (enExample) |
| UA (1) | UA124464C2 (enExample) |
| WO (1) | WO2018005662A1 (enExample) |
| ZA (1) | ZA201808327B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2599791C2 (ru) | 2010-08-10 | 2016-10-20 | Ремпекс Фармасьютикэлз, Инч. | Циклические бороновые кислотно-эфирные производные и их использование в терапии |
| CN105101970B (zh) | 2013-01-10 | 2018-11-20 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| KR102396753B1 (ko) | 2014-06-11 | 2022-05-12 | 베나토알엑스 파마슈티컬스, 인크. | 베타-락타마제 억제제 |
| WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP3347008B1 (en) | 2015-09-11 | 2022-03-09 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| JOP20190188A1 (ar) | 2017-02-01 | 2019-08-01 | Rempex Pharmaceuticals Inc | جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك |
| PH12019502037B1 (en) | 2017-03-06 | 2024-06-05 | Everest Medicines Singapore Pte Ltd | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| US11267826B2 (en) | 2017-05-26 | 2022-03-08 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| EP3630782A4 (en) | 2017-05-26 | 2021-03-03 | Venatorx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| BR112020007138B1 (pt) | 2017-10-11 | 2023-03-21 | Qpex Biopharma, Inc | Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos |
| CN112424209A (zh) * | 2018-04-20 | 2021-02-26 | Qpex生物制药有限公司 | 硼酸衍生物及其治疗用途 |
| US12173018B2 (en) | 2018-05-25 | 2024-12-24 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| DK3886798T3 (da) * | 2018-11-29 | 2026-04-20 | Basilea Pharmaceutica Int Ag Allschwil | Kombinationssammensætninger, som omfatter en beta-lactamase-hæmmer, og anvendelser deraf |
| US12636297B2 (en) | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| TW202123945A (zh) * | 2019-09-13 | 2021-07-01 | 日商鹽野義製藥股份有限公司 | 具有抗菌作用的醫藥組成物 |
| US20230038124A1 (en) * | 2019-10-25 | 2023-02-09 | Sumitomo Pharma Co., Ltd. | Novel substituted condensed ring compound |
| US12637481B2 (en) | 2020-03-18 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| IL297458A (en) | 2020-05-05 | 2022-12-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses |
| TW202214261A (zh) | 2020-08-20 | 2022-04-16 | 大陸商輝諾生物醫藥科技（杭州）有限公司 | 硼酸類化合物 |
| EP4319760A4 (en) * | 2021-04-05 | 2025-01-08 | Qpex Biopharma, Inc. | CEFTIBUTENE DOSAGE REGIMEN |
| CN116917298A (zh) * | 2021-04-13 | 2023-10-20 | 上海拓界生物医药科技有限公司 | 作为β-内酰胺酶抑制剂的硼酸衍生物 |
| CN113150022B (zh) * | 2021-04-23 | 2022-12-06 | 四川大学 | 3-取代五元环状硼酸酯衍生物及其药物组合物和制药用途 |
| CN115557977A (zh) * | 2021-07-02 | 2023-01-03 | 江西济民可信集团有限公司 | 四环类硼酸衍生物作为mbl和/或sbl抑制剂的制备方法和应用 |
| AU2022371538B2 (en) * | 2021-10-19 | 2025-09-25 | Shanghai Jeyou Pharmaceutical Co., Ltd. | Tricyclic boronic acid derivative, and preparation method therefor and application thereof |
| CN119384424A (zh) * | 2022-02-18 | 2025-01-28 | 辉诺生物医药科技（杭州）有限公司 | 新的硼酸类化合物的晶型及其制备方法 |
| CN114716465B (zh) * | 2022-05-06 | 2024-05-24 | 上海中医药大学 | 一种双环硼酸酯类化合物的制备方法及其应用 |
| GB202306835D0 (en) | 2023-05-09 | 2023-06-21 | Adjutec Pharma As | Therapy |
| CN122374318A (zh) | 2023-11-21 | 2026-07-10 | 巴斯利尔药物阿尔施维尔国际股份公司 | 口服递送的β-内酰胺酶抑制剂的柠檬酸盐配位复合物及其用途 |
| CN122374319A (zh) * | 2023-12-04 | 2026-07-10 | 珠海联邦制药股份有限公司 | 硼酸类β-内酰胺酶抑制剂及其制备方法和应用 |
| CN121319015A (zh) * | 2024-09-30 | 2026-01-13 | 科睿迪(南京)医药科技有限公司 | 硼酸衍生物及其制备方法和应用 |
| WO2026104587A1 (en) | 2024-11-13 | 2026-05-21 | Adjutec Pharma As | Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections |
Family Cites Families (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3686398A (en) * | 1970-07-20 | 1972-08-22 | Chevron Res | 10,9-boroxarophenanthrene as fungicides |
| US4194047A (en) | 1975-11-21 | 1980-03-18 | Merck & Co., Inc. | Substituted N-methylene derivatives of thienamycin |
| US4260543A (en) | 1978-07-03 | 1981-04-07 | Merck & Co., Inc. | Crystalline N-formimidoyl thienamycin |
| US4409214A (en) | 1979-11-19 | 1983-10-11 | Fujisawa Pharmaceutical, Co., Ltd. | 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof |
| US4353807A (en) | 1981-03-24 | 1982-10-12 | Mobil Oil Corporation | Lubricants and fuels containing boroxarophenanthrene compounds |
| FR2573070B1 (fr) | 1984-11-13 | 1987-01-30 | Rhone Poulenc Sante | Procede de preparation de composes carbonyles |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US4822786A (en) | 1986-07-01 | 1989-04-18 | Kaken Pharmaceutical Co., Ltd. | Cephalosporin compounds, and antibacterial agents |
| NZ220764A (en) | 1986-07-02 | 1989-09-27 | Shionogi & Co | Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions |
| ZA893284B (en) | 1988-05-04 | 1990-03-28 | Igen Inc | Peptide analogs and their use as haptens to elicit catalytic antibodies |
| US5442100A (en) | 1992-08-14 | 1995-08-15 | The Procter & Gamble Company | β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids |
| US5888998A (en) | 1997-04-24 | 1999-03-30 | Synphar Laboratories, Inc. | 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors |
| US6184363B1 (en) | 1997-06-13 | 2001-02-06 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
| US6075014A (en) | 1997-06-13 | 2000-06-13 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
| WO2000035905A1 (en) | 1998-12-16 | 2000-06-22 | Northwestern University | INHIBITORS OF β-LACTAMASES AND USES THEREFOR |
| AU3124300A (en) | 1998-12-16 | 2000-07-03 | Northwestern University | Inhibitors of beta-lactamases and uses therefor |
| EP1216239B1 (en) | 1999-09-25 | 2004-02-11 | SmithKline Beecham plc | Piperazine derivatives as 5-ht1b antagonists |
| JP2003513890A (ja) | 1999-10-28 | 2003-04-15 | メルク エンド カムパニー インコーポレーテッド | 新規なコハク酸系メタロ−β−ラクタマーゼ阻害薬およびそれの細菌感染治療での使用 |
| WO2002022137A1 (en) | 2000-09-12 | 2002-03-21 | Shoichet Brian K | β-LACTAM ANALOGS AND USES THEREFOR |
| JP2004509122A (ja) | 2000-09-14 | 2004-03-25 | パンセリックス・リミテッド | 抗菌剤としての、３−（ヘテロアリールアセトアミド）−２−オキソ−アゼチジン−１−スルホン酸誘導体 |
| AU2002243508A1 (en) | 2001-01-10 | 2002-07-24 | Bristol-Myers Squibb Company Patent Department | Alpha-aminoboronic acids prepared by novel synthetic methods |
| DE10118698A1 (de) | 2001-04-17 | 2002-11-07 | Jerini Ag | Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche |
| WO2003057144A2 (en) * | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| JP2003229277A (ja) | 2002-02-04 | 2003-08-15 | Matsushita Electric Ind Co Ltd | 発光素子材料およびそれを用いた発光素子並びに装置 |
| AUPS065102A0 (en) | 2002-02-20 | 2002-03-14 | Unisearch Limited | Fluorous acetalation |
| KR100863667B1 (ko) | 2002-09-11 | 2008-10-15 | 가부시끼가이샤 구레하 | 아민 화합물 및 그 용도 |
| EP1571170B1 (en) | 2002-10-30 | 2018-09-05 | Sumitomo Chemical Company, Limited | High-molecular compounds and polymer light emitting devices made by using the same |
| US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
| US6936638B2 (en) | 2002-12-20 | 2005-08-30 | Migenix Corp. | Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto |
| TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
| JP4233365B2 (ja) | 2003-03-25 | 2009-03-04 | 三井化学株式会社 | アザジオール錯体化合物、及び該化合物を用いる光記録媒体 |
| WO2005033090A1 (ja) | 2003-10-06 | 2005-04-14 | Sumitomo Chemical Company, Limited | 芳香族化合物 |
| MXPA06004043A (es) | 2003-10-10 | 2006-06-28 | Pfizer Prod Inc | 2h-[1,2,4]triazolo[4,3-a]pirazinas sustituidas como inhibidores de la glucogeno sintetasa cinasa 3. |
| AU2004288831B2 (en) * | 2003-11-12 | 2010-08-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
| TW200600494A (en) | 2004-03-08 | 2006-01-01 | Chugai Pharmaceutical Co Ltd | Bisphenyl compounds useful as vitamin d3 receptor agonists |
| US20060019116A1 (en) | 2004-07-22 | 2006-01-26 | Eastman Kodak Company | White electroluminescent device with anthracene derivative host |
| TW200618820A (en) | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
| US20060178357A1 (en) | 2005-02-10 | 2006-08-10 | Buynak John D | Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases |
| ES2872962T3 (es) | 2005-02-16 | 2021-11-03 | Anacor Pharmaceuticals Inc | Boronoftalidas para uso terapéutico |
| TWI345562B (en) | 2005-02-22 | 2011-07-21 | Teva Pharma | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof |
| US9184428B2 (en) | 2005-03-15 | 2015-11-10 | Uchicago Argonne Llc | Non-aqueous electrolytes for lithium ion batteries |
| US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
| KR101403164B1 (ko) | 2005-12-07 | 2014-06-03 | 바실리어 파마슈티카 아게 | 베타-락타마아제 저해제 및 모노박탐 항생물질의 유용한조합 |
| RU2642628C2 (ru) | 2006-02-16 | 2018-01-25 | Анакор Фармасьютикалз, Инк. | Бор-содержащие малые молекулы в качестве противовоспалительных средств |
| WO2008039420A2 (en) | 2006-09-27 | 2008-04-03 | Merck & Co., Inc. | Novel inhibitors of beta-lactamase |
| BRPI0809147A2 (pt) | 2007-03-23 | 2014-08-26 | Basilea Pharmaceutica Ag | Medicamentos combinados para tratamento de infecções bacterianas |
| CN101754959B (zh) * | 2007-07-23 | 2014-05-14 | 伊利诺斯大学理事会 | 控制硼酸反应性的体系 |
| CN101939053A (zh) * | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| GB0719366D0 (en) | 2007-10-03 | 2007-11-14 | Smithkline Beecham Corp | Compounds |
| EA201000774A1 (ru) | 2007-11-13 | 2010-12-30 | Новартис Интернэшнл Фармасьютикл Лтд. | Ингибиторы бета-лактамазы |
| US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
| JP5038509B2 (ja) | 2008-01-18 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | β−ラクタマーゼ阻害剤 |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US20100256092A1 (en) | 2008-05-12 | 2010-10-07 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| WO2009139834A1 (en) | 2008-05-13 | 2009-11-19 | Poniard Pharmaceuticals, Inc. | Bioactive compounds for treatment of cancer and neurodegenerative diseases |
| US20120046242A1 (en) | 2008-12-24 | 2012-02-23 | Massachusetts Institute Of Technology | Molecular activators of the wnt/beta-catenin pathway |
| WO2010097675A1 (en) | 2009-02-27 | 2010-09-02 | Dhanuka Laboratories Ltd. | An improved preparation process for cefpodoxime proxetil |
| EP2406233B1 (en) * | 2009-03-09 | 2013-11-13 | Bristol-Myers Squibb Company | Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists |
| US20100292185A1 (en) | 2009-05-12 | 2010-11-18 | Burns Christopher J | Beta-lactamase inhibitors |
| CA2764785C (en) | 2009-06-08 | 2015-10-27 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| EP2458995A1 (en) | 2009-07-28 | 2012-06-06 | Anacor Pharmaceuticals, Inc. | Trisubstituted boron-containing molecules |
| CA2828114A1 (en) | 2010-02-26 | 2011-09-01 | Gary Igor DMITRIENKO | Cephalosporin derivatives useful as .beta.-lactamase inhibitors and compositions and methods of use thereof |
| AU2011235227B2 (en) | 2010-03-31 | 2016-09-08 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| US20110288063A1 (en) | 2010-05-19 | 2011-11-24 | Naeja Pharmaceutical Inc. | Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors |
| US8822516B2 (en) | 2010-06-10 | 2014-09-02 | Technion Research & Development Foundation Limited | Process for the preparation of iodides |
| RU2599791C2 (ru) | 2010-08-10 | 2016-10-20 | Ремпекс Фармасьютикэлз, Инч. | Циклические бороновые кислотно-эфирные производные и их использование в терапии |
| EP3034509B1 (en) | 2010-10-26 | 2020-04-22 | Mars, Incorporated | Arginase inhibitors as therapeutics |
| AU2011329486A1 (en) | 2010-11-18 | 2013-04-18 | Glaxo Group Limited | Compounds |
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| EP2508506A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Preparation of sitagliptin intermediates |
| CN102320960A (zh) | 2011-08-02 | 2012-01-18 | 安徽东健化工科技有限公司 | 一种6-氟水杨酸的制备方法 |
| WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2013053372A1 (en) | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Boronic acid inhibitors of beta-lactamases |
| WO2013056163A1 (en) | 2011-10-14 | 2013-04-18 | The Regents Of The University Of California | Beta-lactamase inhibitors |
| SG10201605152SA (en) | 2011-12-22 | 2016-08-30 | Ares Trading Sa | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| WO2013104897A1 (en) | 2012-01-09 | 2013-07-18 | University of Tromsø | Therapeutic boron-containing compounds |
| EP2615080A1 (en) | 2012-01-12 | 2013-07-17 | LEK Pharmaceuticals d.d. | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof |
| EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| JP6403219B2 (ja) * | 2012-12-07 | 2018-10-10 | ベナトルクス ファーマシューティカルズ，インク． | ベータ−ラクタマーゼ阻害剤 |
| KR20150103270A (ko) | 2013-01-04 | 2015-09-09 | 렘펙스 파머수티클스 인코퍼레이티드 | 보론산 유도체 및 그의 치료적 용도 |
| AU2014204045B2 (en) | 2013-01-04 | 2018-10-18 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN105101970B (zh) | 2013-01-10 | 2018-11-20 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| WO2014151958A1 (en) | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| ES2683329T3 (es) | 2013-03-15 | 2018-09-26 | Intrexon Corporation | Diacilhidrazinas que contienen boro |
| WO2015171398A1 (en) | 2014-05-05 | 2015-11-12 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| US10385074B2 (en) | 2014-05-05 | 2019-08-20 | Rempex Pharmaceuticals, Inc. | Synthesis of boronate salts and uses thereof |
| AU2015264418A1 (en) | 2014-05-19 | 2016-11-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| KR102396753B1 (ko) | 2014-06-11 | 2022-05-12 | 베나토알엑스 파마슈티컬스, 인크. | 베타-락타마제 억제제 |
| AU2015284307A1 (en) | 2014-07-01 | 2017-02-02 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2016065282A1 (en) | 2014-10-24 | 2016-04-28 | The Regents Of The University Of Michigan | Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels |
| WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| US20170252351A1 (en) | 2015-01-24 | 2017-09-07 | Wockhardt Limited | Antibacterial Compositions |
| WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2016172208A1 (en) | 2015-04-24 | 2016-10-27 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| AU2017295866A1 (en) | 2016-07-14 | 2019-01-17 | Achaogen, Inc. | Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections |
| CN106397455B (zh) | 2016-08-30 | 2018-08-31 | 山东罗欣药业集团恒欣药业有限公司 | 一种抗感染药物头孢布烯晶体化合物及其组合物 |
| CN106397454B (zh) | 2016-08-30 | 2018-08-24 | 山东罗欣药业集团股份有限公司 | 一种抗感染药物头孢布烯晶型化合物及其组合物 |
| SG11201901658PA (en) | 2016-09-16 | 2019-04-29 | Entasis Therapeutics Ltd | Beta-lactamase inhibitor compounds |
| CN106420617A (zh) | 2016-09-21 | 2017-02-22 | 临沂草之美医药科技有限公司 | 一种治疗外科手术感染的药物头孢布烯粉针剂 |
| CN106432271A (zh) | 2016-09-21 | 2017-02-22 | 临沂草之美医药科技有限公司 | 一种治疗外科手术感染的药物头孢布烯晶体化合物 |
| CN106397457A (zh) | 2016-09-21 | 2017-02-15 | 临沂草之美医药科技有限公司 | 一种治疗外科手术感染的药物头孢布烯晶体化合物 |
| CN106432270A (zh) | 2016-09-21 | 2017-02-22 | 临沂草之美医药科技有限公司 | 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法 |
| CN106420760A (zh) | 2016-09-21 | 2017-02-22 | 临沂草之美医药科技有限公司 | 一种治疗外科手术感染的药物头孢布烯组合物 |
| CN106432272A (zh) | 2016-09-21 | 2017-02-22 | 临沂草之美医药科技有限公司 | 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法 |
| US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
| BR112020007138B1 (pt) | 2017-10-11 | 2023-03-21 | Qpex Biopharma, Inc | Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos |
| WO2019093450A1 (ja) | 2017-11-10 | 2019-05-16 | 塩野義製薬株式会社 | ジアザビシクロオクタン誘導体 |
| CN112424209A (zh) | 2018-04-20 | 2021-02-26 | Qpex生物制药有限公司 | 硼酸衍生物及其治疗用途 |
| CN109293678A (zh) | 2018-11-20 | 2019-02-01 | 湖北凌晟药业有限公司 | 一种头孢布烯的制备方法 |
| DK3886798T3 (da) | 2018-11-29 | 2026-04-20 | Basilea Pharmaceutica Int Ag Allschwil | Kombinationssammensætninger, som omfatter en beta-lactamase-hæmmer, og anvendelser deraf |
| US12636297B2 (en) | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP4021443A1 (en) | 2019-08-29 | 2022-07-06 | Arixa Pharmaceuticals, Inc. | Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections |
| US12637481B2 (en) | 2020-03-18 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| IL297458A (en) | 2020-05-05 | 2022-12-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses |
| EP4319760A4 (en) | 2021-04-05 | 2025-01-08 | Qpex Biopharma, Inc. | CEFTIBUTENE DOSAGE REGIMEN |
| JP2024524372A (ja) | 2021-07-01 | 2024-07-05 | キューペックス バイオファーマ， インコーポレイテッド | セフチブテンの結晶形態 |
-
2017
- 2017-06-28 AU AU2017290060A patent/AU2017290060B2/en active Active
- 2017-06-28 PT PT17821161T patent/PT3478693T/pt unknown
- 2017-06-28 KR KR1020197003015A patent/KR102403296B1/ko active Active
- 2017-06-28 UA UAA201812390A patent/UA124464C2/uk unknown
- 2017-06-28 CA CA3026582A patent/CA3026582A1/en active Pending
- 2017-06-28 MY MYPI2018002676A patent/MY196909A/en unknown
- 2017-06-28 JP JP2018565257A patent/JP7060245B2/ja active Active
- 2017-06-28 CN CN201780041247.XA patent/CN109415386B/zh active Active
- 2017-06-28 EP EP17821161.1A patent/EP3478693B1/en active Active
- 2017-06-28 PL PL17821161T patent/PL3478693T3/pl unknown
- 2017-06-28 US US15/636,424 patent/US10294249B2/en active Active
- 2017-06-28 BR BR112018077015-9A patent/BR112018077015B1/pt active IP Right Grant
- 2017-06-28 WO PCT/US2017/039787 patent/WO2018005662A1/en not_active Ceased
- 2017-06-28 ES ES17821161T patent/ES2894251T3/es active Active
- 2017-06-28 MX MX2018015892A patent/MX389349B/es unknown
- 2017-06-28 DK DK17821161.1T patent/DK3478693T3/da active
- 2017-06-28 SG SG11201811549UA patent/SG11201811549UA/en unknown
-
2018
- 2018-12-03 IL IL263450A patent/IL263450B/en unknown
- 2018-12-10 ZA ZA2018/08327A patent/ZA201808327B/en unknown
- 2018-12-19 CL CL2018003681A patent/CL2018003681A1/es unknown
- 2018-12-21 CO CONC2018/0013978A patent/CO2018013978A2/es unknown
- 2018-12-21 PH PH12018502747A patent/PH12018502747A1/en unknown
- 2018-12-25 SA SA518400742A patent/SA518400742B1/ar unknown
-
2019
- 2019-04-08 US US16/378,323 patent/US10570159B2/en active Active
-
2020
- 2020-02-18 US US16/793,965 patent/US11180512B2/en active Active
-
2021
- 2021-11-05 US US17/520,365 patent/US11999759B2/en active Active
-
2024
- 2024-04-17 US US18/638,558 patent/US12509475B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018013978A2 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos. | |
| CY1124726T1 (el) | Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX2020003495A (es) | Derivados de acido boronico y sintesis de los mismos. | |
| DOP2015000274A (es) | Compuestos químicos | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| CR20170077A (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| NI201500096A (es) | Compuesto químicos | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| DOP2017000018A (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| BR112017009850A2 (pt) | composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto | |
| ECSP18056196A (es) | Derivados de indano | |
| BR112017009852A2 (pt) | composto, composição, e, usos de um composto | |
| BR112017009853A2 (pt) | composto, composição, uso de uma quantidade melhoradora de hiv de um composto |